Literature DB >> 24531242

Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity.

Hung The Dang1, Erik Chorell, Hanna Uvell, Jerome S Pinkner, Scott J Hultgren, Fredrik Almqvist.   

Abstract

Developing new compounds targeting virulence factors (e.g., inhibition of pilus assembly by pilicides) is a promising approach to combating bacterial infection. A high-throughput screening campaign of a library of 17 500 small molecules identified 2-amino-3-acyl-tetrahydrobenzothiophene derivatives (hits 2 and 3) as novel inhibitors of pili-dependent biofilm formation in a uropathogenic Escherichia coli strain UTI89. Based on compounds 2 and 3 as the starting point, we designed and synthesized a series of structurally related analogs and investigated their activity against biofilm formation of E. coli UTI89. Systematic structural modification of the initial hits provided valuable information on their SARs for further optimization. In addition, small structural changes to the parent molecules resulted in low micromolar inhibitors (20-23) of E. coli biofilm development without an effect on bacterial growth. The hit compound 3 and its analog 20 were confirmed to prevent pili formation in a hemagglutination (HA) titer assay and electron microscopy (EM) measurements. These findings suggest that 2-amino-3-acyl-tetrahydrobenzothiophenes may serve as a new class of compounds for further elaboration as antibacterial agents with antivirulence activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531242      PMCID: PMC4151345          DOI: 10.1039/c3ob42478b

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  33 in total

1.  Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity.

Authors:  Erik Chorell; Jerome S Pinkner; Gilles Phan; Sofie Edvinsson; Floris Buelens; Han Remaut; Gabriel Waksman; Scott J Hultgren; Fredrik Almqvist
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

2.  Pilicides-small molecules targeting bacterial virulence.

Authors:  Veronica Aberg; Fredrik Almqvist
Journal:  Org Biomol Chem       Date:  2007-04-20       Impact factor: 3.876

Review 3.  Targeting virulence: a new paradigm for antimicrobial therapy.

Authors:  Anne E Clatworthy; Emily Pierson; Deborah T Hung
Journal:  Nat Chem Biol       Date:  2007-09       Impact factor: 15.040

Review 4.  The biology and future prospects of antivirulence therapies.

Authors:  Lynette Cegelski; Garland R Marshall; Gary R Eldridge; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

5.  Urologic diseases in America Project: analytical methods and principal findings.

Authors:  Mark S Litwin; Christopher S Saigal; Elizabeth M Yano; Chantal Avila; Sandy A Geschwind; Jan M Hanley; Geoffrey F Joyce; Rodger Madison; Jennifer Pace; Suzanne M Polich; Mingming Wang
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

6.  Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.

Authors:  M A Mulvey; Y S Lopez-Boado; C L Wilson; R Roth; W C Parks; J Heuser; S J Hultgren
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

7.  Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.

Authors:  Patricia L Podolin; James F Callahan; Brian J Bolognese; Yue H Li; Karey Carlson; T Gregg Davis; Geoff W Mellor; Christopher Evans; Amy K Roshak
Journal:  J Pharmacol Exp Ther       Date:  2004-08-17       Impact factor: 4.030

Review 8.  Productive steps toward an antimicrobial targeting virulence.

Authors:  Amy K Barczak; Deborah T Hung
Journal:  Curr Opin Microbiol       Date:  2009-07-22       Impact factor: 7.934

9.  Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation.

Authors:  Lynette Cegelski; Jerome S Pinkner; Neal D Hammer; Corinne K Cusumano; Chia S Hung; Erik Chorell; Veronica Aberg; Jennifer N Walker; Patrick C Seed; Fredrik Almqvist; Matthew R Chapman; Scott J Hultgren
Journal:  Nat Chem Biol       Date:  2009-10-25       Impact factor: 15.040

10.  Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria.

Authors:  Jerome S Pinkner; Han Remaut; Floris Buelens; Eric Miller; Veronica Aberg; Nils Pemberton; Mattias Hedenström; Andreas Larsson; Patrick Seed; Gabriel Waksman; Scott J Hultgren; Fredrik Almqvist
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-10       Impact factor: 11.205

View more
  5 in total

Review 1.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

Review 2.  Therapeutic Approaches Targeting the Assembly and Function of Chaperone-Usher Pili.

Authors:  John J Psonis; David G Thanassi
Journal:  EcoSal Plus       Date:  2019-03

Review 3.  Urinary Tract Infection: Pathogenesis and Outlook.

Authors:  Lisa K McLellan; David A Hunstad
Journal:  Trends Mol Med       Date:  2016-09-28       Impact factor: 11.951

4.  Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.

Authors:  Sarah E Greene; Jerome S Pinkner; Erik Chorell; Karen W Dodson; Carrie L Shaffer; Matt S Conover; Jonathan Livny; Maria Hadjifrangiskou; Fredrik Almqvist; Scott J Hultgren
Journal:  mBio       Date:  2014-10-28       Impact factor: 7.867

Review 5.  Pathophysiology, Clinical Importance, and Management of Neurogenic Lower Urinary Tract Dysfunction Caused by Suprasacral Spinal Cord Injury.

Authors:  H Z Hu; N Granger; N D Jeffery
Journal:  J Vet Intern Med       Date:  2016-08-16       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.